Oliver Luxxe Assets LLC Invests $3.97 Million in Stryker Corporation $SYK

Oliver Luxxe Assets LLC bought a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, HoldingsChannel reports. The fund bought 12,605 shares of the medical technology company’s stock, valued at approximately $3,969,000.

Several other large investors have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. acquired a new stake in Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new position in Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Up 0.4%

Shares of SYK opened at $338.85 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock has a market cap of $129.97 billion, a price-to-earnings ratio of 35.11, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The firm has a 50 day simple moving average of $320.11 and a 200-day simple moving average of $334.13.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of recent analyst reports. BMO Capital Markets assumed coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Argus set a $370.00 target price on Stryker in a report on Thursday, July 9th. Evercore set a $350.00 target price on shares of Stryker in a research report on Monday, July 6th. Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, Barclays reduced their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 over the last quarter. Insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.